Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Breast 4Genitourinary 2Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 678Cytarabine 576fludarabine 410fludarabine phosphate 387venetoclax 310Methotrexate 297Rituximab 283Azacitidine 264Busulfan 248Whole-Body Irradiation 220Etoposide 215Filgrastim 214Peripheral Blood Stem Cell Transplantation 211Mycophenolic Acid 206Tacrolimus 196Dexamethasone 191Granulocyte Colony-Stimulating Factor 182Vincristine 173Melphalan 173Decitabine 163Cyclosporine 146Daunorubicin 139Antilymphocyte Serum 137Idarubicin 134Imatinib Mesylate 127Lenalidomide 116Doxorubicin 109Radiotherapy 108Stem Cell Transplantation 107Clofarabine 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lovastatin × Other hematologic neoplasm × Clear all
NCT00583102 2018-01-05

Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML

University of Iowa

Phase 1/2 Terminated
23 enrolled 8 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡